PDCD1 and colorectal adenocarcinoma: As reported at the 2019 Annual Meeting of the American Society of Clinical Oncology, the combination of anti-PD-1 monoclonal antibody nivolumab and angiopoietin receptor/VEGFR inhibitor regorafenib was found to yield promising objective responses in chemotherapy-refractory gastric adenocarcinoma and colorectal adenocarcinoma.